https://www.oncobites.tv/esmo25videos/artemis-002-y-esquema-chino-de-legubicin-para-sarcoma%2C-protocolos-que-prometen 2026-04-13 https://www.oncobites.tv/esmo25videos/impresiones-en-vivo-desde-esmo-2025 2026-04-13 https://www.oncobites.tv/esmo25videos/gem1801%3A-nuevos-datos-espa%C3%B1oles-sobre-inmunoterapia-en-melanoma 2026-04-13 https://www.oncobites.tv/esmo25videos/nuevas-fronteras-en-c%C3%A1ncer-de-pulm%C3%B3n-egfr%3A-%C2%BFqu%C3%A9-revelan-los-estudios-laura%2C-northstar%2C-flaura2%2C-savannah%2C-sachi-y-adaura%3F 2026-04-13 https://www.oncobites.tv/esmo25videos/tras-la-progresi%C3%B3n-a-inhibidores-de-tki-en-c%C3%A1ncer-de-pulm%C3%B3n-egfr%2B%2C-%C2%BFestamos-ante-un-nuevo-est%C3%A1ndar-de-tratamiento%3F 2026-04-13 https://www.oncobites.tv/esmo25videos/harmonie-6-dellphi-303%2C-avances-para-tratamiento-del-c%C3%A1ncer-de-pulm%C3%B3n-her2%2B-(soho-01-y-beamion-lung-1 2026-04-13 https://www.oncobites.tv/esmo25videos/an%C3%A1lisis-de-los-pros-con-cemiplimab-y-su-impacto-en-la-os 2026-04-13 https://www.oncobites.tv/esmo25videos/actualizaci%C3%B3n-del-alina%2C-estudio-elevate%2C-5-a%C3%B1os-de-seguimiento-del-keynote-671%2C-estudio-canadiense-cctg-br.31%2C-an%C3%A1lisis-exploratorio-del-eagean 2026-04-13 https://www.oncobites.tv/esmo25videos/estudio-mdt-bridge%3A-la-evaluaci%C3%B3n-multidisciplinar-din%C3%A1mica-redefine-la-resecabilidad-en-c%C3%A1ncer-de-pulm%C3%B3n 2026-04-13 https://www.oncobites.tv/esmo25videos/swog-s1801%2C-nadina%2C-simplificaci%C3%B3n-de-la-neoadyuvancia%2C-tratamiento-para-el-melanoma-uveal%2C-herramienta-prometedora-de-machine 2026-04-13 https://www.oncobites.tv/esmo25videos/bnt111-01%3A-vacuna-de-arn-en-combinaci%C3%B3n-con-cemiplimab-muestra-actividad-cl%C3%ADnica-en-melanoma-avanzado-refractario-a-inmunoterapia 2026-04-13 https://www.oncobites.tv/esmo25videos/c-post-suban%C3%A1lisis-de-segundos-tumores-primarios-y-datos-de-respuesta-patol%C3%B3gica-neo-y-adyuvante.-agenonmela%2C-biopsia-l%C3%ADquida-y-cemiplimab.-daromun.-nuevas-combinaciones-para-c%C3%A1ncer-no-melanoma-y-datos-de-c%C3%A1ncer-de-merkel 2026-04-13 https://www.oncobites.tv/esmo25videos/novedades-en-cemiplimab-para-carcinoma-cut%C3%A1neo-escamoso%3A-suban%C3%A1lisis-de-c-post-y-case 2026-04-13 https://www.oncobites.tv/esmo25videos/avances-y-futuro-del-tratamiento-en-c%C3%A1ncer-de-pr%C3%B3stata-avanzado 2026-04-13 https://www.oncobites.tv/esmo25videos/un-f%C3%A1rmaco-dirigido-a-una-poblaci%C3%B3n-con-un-biomarcador-espec%C3%ADfico-logra-un-resultado-positivo%2C-pero%2C-%C2%BFes-este-beneficio-realmente-significativo%3F 2026-04-13 https://www.oncobites.tv/esmo25videos/estudio-pr.21-del-canadian-cancer-trials-group-(cctg) 2026-04-13 https://www.oncobites.tv/esmo25videos/abre-la-posibilidad-de-tripleta-de-intensificaci%C3%B3n-de-radioligandos-con-lutecio-%2B-adt-%2B-arpi.-medicina-de-precisi%C3%B3n-en-c%C3%A1ncer-de-pr%C3%B3stata. 2026-04-13 https://www.oncobites.tv/esmo25videos/potomac%2C-alban%2C-ev-303%2C-imvigor011%2C-checkmate-274-y-estudio-de-disitamab-vedotin 2026-04-13 https://www.oncobites.tv/esmo25videos/keynote-905%2Fev-303%2C-datos-y-hechos-para-c%C3%A1ncer-de-vejiga 2026-04-13 https://www.oncobites.tv/esmo25videos/--rampart%3A-%C2%BFpodr%C3%ADa-una-nueva-combinaci%C3%B3n-de-inmunoterapia-adyuvante-cambiar-el-pron%C3%B3stico-tras-la-cirug%C3%ADa-del-c%C3%A1ncer-de-ri%C3%B1%C3%B3n%3F---nescio%3A-%C2%BFes-posible-eliminar-por-completo-el-tumor-antes-de-la-cirug%C3%ADa-con-las-nuevas-combinaciones-de-inmunoterapia-neoadyuvante%3F---clear%3A-%C2%BFqu%C3%A9-nuevos-datos-de-eficacia-ofrece-la-combinaci%C3%B3n-de-lenvatinib-y-pembrolizumab-en-pacientes-con-met%C3%A1stasis-%C3%B3seas%3F---keynote-u3a%3A-%C2%BFcu%C3%A1l-es-el-potencial-de-las-nuevas-combinaciones-triples-basadas-en-lenvatinib-y-pembrolizumab-en-primera-l%C3%ADnea%3F---calypso%3A-%C2%BFqu%C3%A9-nos-dice-el-an%C3%A1lisis-molecular-final-sobre-la-actividad-de-cabozantinib-y-nivolumab-en-subgrupos-espec%C3%ADficos%3F---lencabo%3A-en-segunda-l%C3%ADnea%2C-%C2%BFqu%C3%A9-terapia-demuestra-ser-superior-tras-el-fracaso-de-la-inmunoterapia%2C-lenvatinib-o-cabozantinib%3F---mk-012%3A-%C2%BFconfirmar%C3%A1-el-estudio-fase-3-mk-012-el-potencial-de-las-nuevas-combinaciones-exploradas-en-primera-l%C3%ADnea%3F 2026-04-13 https://www.oncobites.tv/esmo25videos/estudio-lencabo%3A-cabozantinib-frente-a-lenvatinib-everolimus-en-c%C3%A1ncer-de-ri%C3%B1%C3%B3n-avanzado-post-inmunoterapia 2026-04-13 https://www.oncobites.tv/esmo25videos/maneuver%2Cinmunosarc-ii%2C-artemis-002%2C-estudio-chino-con-legubicin-y-ensayos-fase-1-y-2-en-diferentes-enfermedades-raras 2026-04-13 https://www.oncobites.tv/esmo25videos/camoral%2C-3-estudios-anti-pd-l1%2C-aspen-04%2C-origami%2C-bd4qol-y-capecitabina-%2B-quimioradioterapia-en-c%C3%A1ncer-nasofar%C3%ADngeo- 2026-04-13 https://www.oncobites.tv/esmo25videos/d 2026-04-13 https://www.oncobites.tv/esmo25videos/keynote-b96%2C-duo-o%2C-rosella-y-optimizaci%C3%B3n-de-dosis-del-radulotatug-deruxtecan 2026-04-13 https://www.oncobites.tv/esmo25videos/keynote-b96%2C-beneficio-significativo-de-io-en-c%C3%A1ncer-de-ovario 2026-04-13 https://www.oncobites.tv/esmo25videos/sacituzumab-tirumotecan-para-c%C3%A1ncer-cervical.-leap-001%2C-rainfol-01-y-nuevo-adc-para-c%C3%A1ncer-de-endometrio 2026-04-13 https://www.oncobites.tv/esmo25videos/atenci%C3%B3n-al-esquema-propuesto-en-el-keynote-a18-para-c%C3%A1ncer-cervical 2026-04-13 https://www.oncobites.tv/esmo25videos/cares-009%2C-abc%2C-talentop%2C-prodige-81-y-el-imbrabe%2Fskysrapper 2026-04-13 https://www.oncobites.tv/esmo25videos/virage%3A-espa%C3%B1oles-estudian-oncovirus-para-tratar-el-c%C3%A1ncer-de-p%C3%A1ncreas 2026-04-13 https://www.oncobites.tv/esmo25videos/matterhorn%2C-kc-wise%2C-estudios-con-anticlaudina-18.2%2C-y-4-ensayos-cuyos-resultados-fueron-negativos-(periscope%2C-leap-014%2C-skyscraper-07-e-intergrate-iib) 2026-04-13 https://www.oncobites.tv/esmo25videos/fortitude-101-preguntas-y-respuestas-de-los-resultados-del-estudio 2026-04-13 https://www.oncobites.tv/esmo25videos/dynamic-iii%2C-pegasus%2C-destiny-crc02%2C-breakwater%2C-ca209-8hw 2026-04-13 https://www.oncobites.tv/esmo25videos/stellar-303-en-c%C3%A1ncer-colorrectal-mss%2C-refractario 2026-04-13 https://www.oncobites.tv/esmo25videos/natalee-y-monarche 2026-04-13 https://www.oncobites.tv/esmo25videos/destiny-005-y-011 2026-04-13 https://www.oncobites.tv/esmo25videos/positive%2C-estudio-indio-de-pembrolizumab-a-bajas-dosis%2C-geparnuevo-y-el-empress 2026-04-13 https://www.oncobites.tv/esmo25videos/an%C3%A1lisis-preliminar-del-estudio-solti-ribolaris 2026-04-13 https://www.oncobites.tv/esmo25videos/ascent-03%2C-tropion-breast02-para-triple-negativo-y-db09-en-her2%2B 2026-04-13 https://www.oncobites.tv/esmo25videos/evera%2C-viktoria-1%2C-serena-6-%2C-sonia 2026-04-13 https://www.oncobites.tv/esmo25videos/estrategias-en-ebc%3A-triple-negativo%2C-luminal-y-her2%2B 2026-04-13 https://www.oncobites.tv/esmo25videos/c%C3%A1ncer-de-mama-en-poblaciones-especiales 2026-04-13 https://www.oncobites.tv/esmo25videos/p%C3%B3sters-destacados-en-mama-luminal%3A-natalee%2C-real-world-ribociclib%2C-en-canad%C3%A1.--ribociclib-%2B-palazestrant%2C-capitello-291 2026-04-13 https://www.oncobites.tv/esmo25videos/avances-en-c%C3%A1ncer-de-mama-triple-negativo-y-her2%2B%3A-estudio-sueco-en-triple-negativo%2C-wsg-adapt-tn-iii%2C-inmunoconjugado-muc1-e-inavolisib-en-combinaci%C3%B3n-con-dos-anticuerpos-monoclonales 2026-04-13